Companion Diagnostic Tests Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Market Dynamics of Companion Diagnostic Tests Market Analysis
Growth Drivers
- Growth in Precision Medicine
- Increasing Approvals for Targeted Therapies boost demand
- Technological Advancements in Genomics and Molecular Diagnostics is fueling the market
Restraints
- High Cost of Development and Testing limit market growth
- Complex Regulatory Approval Process can hinder market adoption
Trends
- Integration of AI and Big Data Analytics
- Development of Multi-gene Panel Tests
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
Companion Diagnostic Tests Market Analysis — Presence
Geographical Analysis
Click countries to exploreRegional and Country Analysis
Global Companion Diagnostic Tests Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| Global | xxxx | xxxx | $ 19 Million | 13.5% |
| North America | xxxx | $ 2683.02 Million | $ 6318.1 Million | 11.3% |
| United States | xxxx | $ 2116.9 Million | xxxx | 11.1% |
| Canada | xxxx | $ 321.96 Million | xxxx | 12.1% |
| Mexico | xxxx | $ 244.15 Million | xxxx | 11.8% |
| Europe | xxxx | $ 2102.91 Million | $ 5132.8 Million | 11.8% |
| United Kingdom | xxxx | $ 353.29 Million | xxxx | 12.6% |
| France | xxxx | $ 193.47 Million | xxxx | 11% |
| Germany | xxxx | $ 416.38 Million | xxxx | 12% |
| Italy | xxxx | $ 180.85 Million | xxxx | 11.2% |
| Russia | xxxx | $ 325.95 Million | xxxx | 10.8% |
| Spain | xxxx | $ 172.44 Million | xxxx | 10.9% |
| Sweden | xxxx | $ 65.19 Million | xxxx | 11.9% |
| Denmark | xxxx | $ 44.16 Million | xxxx | 11.6% |
| Switzerland | xxxx | $ 31.54 Million | xxxx | 11.5% |
| Luxembourg | xxxx | $ 25.23 Million | xxxx | 12.1% |
| Rest of Europe | xxxx | $ 294.41 Million | xxxx | 10.5% |
| Asia Pacific | xxxx | $ 1740.34 Million | $ 5511.7 Million | 15.5% |
| China | xxxx | $ 730.94 Million | xxxx | 15% |
| Japan | xxxx | $ 240.17 Million | xxxx | 14% |
| South Korea | xxxx | $ 208.84 Million | xxxx | 14.6% |
| India | xxxx | $ 174.03 Million | xxxx | 17.4% |
| Australia | xxxx | $ 90.5 Million | xxxx | 14.8% |
| Singapore | xxxx | $ 34.81 Million | xxxx | 15.8% |
| Taiwan | xxxx | $ 67.87 Million | xxxx | 15.3% |
| South East Asia | xxxx | $ 114.86 Million | xxxx | 16.3% |
| Rest of APAC | xxxx | $ 78.32 Million | xxxx | 15.3% |
| South America | xxxx | $ 275.55 Million | $ 707 Million | 12.5% |
| Brazil | xxxx | $ 117.94 Million | xxxx | 13.1% |
| Argentina | xxxx | $ 46.29 Million | xxxx | 13.4% |
| Colombia | xxxx | $ 24.52 Million | xxxx | 12.3% |
| Peru | xxxx | $ 22.6 Million | xxxx | 12.7% |
| Chile | xxxx | $ 19.84 Million | xxxx | 12.8% |
| Rest of South America | xxxx | $ 44.36 Million | xxxx | 11.6% |
| Middle East | xxxx | $ 290.06 Million | $ 760.2 Million | 12.8% |
| Saudi Arabia | xxxx | $ 102.1 Million | xxxx | 13.1% |
| Turkey | xxxx | $ 23.2 Million | xxxx | 13.4% |
| UAE | xxxx | $ 59.75 Million | xxxx | 13.3% |
| Egypt | xxxx | $ 17.4 Million | xxxx | 12.6% |
| Qatar | xxxx | $ 23.2 Million | xxxx | 12.3% |
| Rest of Middle East | xxxx | $ 64.39 Million | xxxx | 12% |
| Africa | xxxx | $ 159.53 Million | $ 430.1 Million | 13.2% |
| East Africa | xxxx | xxxx | xxxx | xxxx |
| West Africa | xxxx | xxxx | xxxx | xxxx |
| North Africa | xxxx | xxxx | xxxx | xxxx |
| South Africa | xxxx | $ 56.15 Million | xxxx | 14.1% |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
How are Segments Performing in the Global Companion Diagnostic Tests Market? Companion Diagnostic Tests Market Product Type Analysis According to Cognitive Market Research, Immunohistochemistry is likely to dominate the Companion Diagnostic Tests Market. Companion diagnostic tests play a crucial role in the field of immunohistochemistry (IHC), particularly in the personalized medicine landscape. These tests are designed to identify specific biomarkers within tissue samples, which can help determine whether a patient is likely to benefit from a particular targeted therapy. In IHC, antibodies are used to detect the presence and distribution of proteins expressed in cells, and companion diagnostics harness this technology to provide clinically relevant information that guides treatment decisions. Companies like Roche, Agilent Technologies, and Danaher Corporation have integrated digital pathology with IHC. For instance, in June 2024, Roche received FDA 510(k) clearance for its VENTANA DP 200 system, enhancing digital slide interpretation. DNA Detection is the fastest-growing segment in the Companion Diagnostic Tests market. The usage of companion diagnostic tests in DNA detection involves advanced molecular techniques, such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH). These technologies allow for precise identification of genetic alterations at the DNA level, facilitating early diagnosis, treatment selection, and monitoring of disease progression. By integrating companion diagnostics into clinical workflows, healthcare providers can make informed decisions based on a patient’s unique genetic makeup. This not only improves treatment outcomes but also reduces unnecessary exposure to ineffective therapies, ultimately enhancing the overall efficiency of healthcare delivery. In May 2025, researchers at the Indian Institute of Technology, Indore (IIT-I), developed a Quantum AI nanotechnology that enables early and accurate detection of genetic mutations, including those related to cancer. This technology integrates quantum transport with explainable artificial intelligence, offering a cost-effective, high-resolution solution for unified DNA sequencing.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Companion Diagnostic Tests Market
The Companion Diagnostic Tests market is highly competitive, characterized by the presence of several global and regional players offering a wide range of products. Key companies in the market, such as Abbott, F. Hoffmann-LA Roche AG, Genomic Health, Inc., QIAGEN, Agilent Technologies, Inc dominate through their extensive product portfolios, strong distribution networks, and focus on innovation.
In January 2024, Agilent partnered with Incyte to develop companion diagnostics supporting Incyte's hematology and oncology portfolio, expanding Agilent's biomarker offerings. https://www.agilent.com/about/newsroom/presrel/2024/30jan-ca24002.html" In August 2023, QIAGEN obtained FDA approval for a companion diagnostic to aid therapy selection for gastrointestinal stromal tumors in collaboration with Blueprint Medicines’ AYVAKIT. https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2023/QIAGEN-receives-FDA-approval-for-companion-diagnostic-to-Blueprint-Medicines-AYVAKIT-avapritinib-in-gastrointestinal-stromal-tumors/default.aspx/"
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Abbott | ••• | ••• | ••• | ••• |
| F. Hoffmann-LA Roche AG | ••• | ••• | ••• | ••• |
| Genomic Health | ••• | ••• | ••• | ••• |
| Inc. | ••• | ••• | ••• | ••• |
| QIAGEN | ••• | ••• | ••• | ••• |
| Agilent Technologies | ••• | ••• | ••• | ••• |
| Inc. | ••• | ••• | ••• | ••• |
| AGENDIA N.V. | ••• | ••• | ••• | ••• |
| bioMérieux SA | ••• | ••• | ••• | ••• |
| Illumina | ••• | ••• | ••• | ••• |
| Inc. | ••• | ••• | ••• | ••• |
| Siemens Healthineers | ••• | ••• | ••• | ••• |
| Thermo Fisher Scientific Inc. | ••• | ••• | ••• | ••• |
| BioGenex | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
According to Cognitive Market Research, the global Companion Diagnostic Tests market size will be USD 7,251.4 million in 2025. It will expand at a compound annual growth rate (CAGR) of 13.50% from 2025 to 2033.
- North America held the major market share for more than 37% of the global revenue with a market size of USD 2683.02 million in 2025 and will grow at a compound annual growth rate (CAGR) of 11.3% from 2025 to 2033.
- Europe accounted for a market share of over 29% of the global revenue with a market size of USD 2102.91 million.
- APAC held a market share of around 24% of the global revenue with a market size of USD 1740.34 million in 2025 and will grow at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2033.
- South America has a market share of more than 3.8% of the global revenue with a market size of USD 275.55 million in 2025 and will grow at a compound annual growth rate (CAGR) of 12.5% from 2025 to 2033.
- Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 290.06 million in 2025 and will grow at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2033.
- Africa had a market share of around 2.2% of the global revenue and was estimated at a market size of USD 159.53 million in 2025 and will grow at a compound annual growth rate (CAGR) of 13.2% from 2025 to 2033.
- Protein Detection is the fastest growing segment of the Companion Diagnostic Tests industry
Introduction of the Companion Diagnostic Tests Market
Companion Diagnostic Tests (CDx) are in vitro diagnostic tools used to determine the suitability of a specific therapeutic product for a particular patient. These tests help identify biomarkers or genetic mutations that predict a patient's response to a drug, thus enabling personalized treatment strategies. CDx are primarily used in oncology but are increasingly being applied to other areas such as cardiology, neurology, and infectious diseases. Their main utility lies in selecting patients most likely to benefit from a given therapy, avoiding adverse effects, and optimizing treatment outcomes. As such, they play a critical role in the safe and effective use of targeted drugs.
In August 2023, Agilent received European IVDR certification for its companion diagnostic assay, aligning with the EU's updated regulatory standards. https://www.agilent.com/about/newsroom/presrel/2025/17apr-ca25010.htm”
Impact of Trump Tariffs on the Companion Diagnostic Tests Market
The immediate and direct impacts of these tariffs has been the increased cost burden on U.S.-based diagnostic companies. Manufacturers such as Roche, Qiagen, Thermo Fisher Scientific, and Illumina—key players in the companion diagnostics space—have had to either absorb higher costs or pass them on to consumers and healthcare providers. This has led to elevated pricing for CDx kits and potentially hindered adoption, especially among smaller healthcare providers and research labs with limited budgets. Additionally, delays in supply chain logistics and the increased cost of raw materials have slowed down innovation and commercialization timelines for new CDx products.
The Trump administration’s tariffs, many of which remain in place as of 2025, continue to reverberate through the medical diagnostics sector, particularly the high-growth Companion Diagnostic (CDx) tests segment. These tariffs introduced primarily under Sections 232 and 301 of the Trade Expansion Act targeted medical equipment and chemical components among a broader set of Chinese imports. Given that a large portion of CDx components, including reagents, plasticware, and semiconductor chips for lab instruments, are imported from China and East Asia, these tariffs have had a significant cascading effect across the value chain.
Companion diagnostic tests are co-developed with specific drug therapies and require advanced molecular testing platforms such as PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), and immunohistochemistry. A 25% tariff on imported lab equipment and raw materials from China has increased capital and operational expenditures for diagnostic firms. Based on recent industry surveys, the average cost of producing a CDx assay rose by 12%–15% between 2018 and 2024, with a disproportionate impact on small and mid-sized biotech firms.
Analyst Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Companion Diagnostic Tests Market Analysis is witnessing significant growth in the near future.
In 2023, the Detection Technique segment accounted for a notable share of the Companion Diagnostic Tests Market Analysis.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
Frequently Asked Questions
★ Reviews
Rate this report
Companion Diagnostic Tests Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| By Product Type Outlook: | Detection Technique, Protein Detection, Immunohistochemistry, DNA Detection, Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), In Situ Hybridization, Others, Biomarker, EGFR, KRAS, HER2, BRAF V600E, Others |
|---|---|
| By Cancer Type Outlook: | Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma, Others |
| By End-User Outlook: | Hospitals, Specialty Clinics, Diagnostic Labs, Others |
| List of Competitors | Abbott, F. Hoffmann-LA Roche AG, Genomic Health, Inc., QIAGEN, Agilent Technologies, Inc., AGENDIA N.V., bioMérieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., BioGenex |
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Global Companion Diagnostic Tests Market Analysis by Key Players
- 1.1.2 Segment Market Analysis by Key Players
- 1.1.3 Top Players Ranking 2024
- 1.1.4 New Product Launch Analysis
- 1.1.5 Industry Mergers and Acquisition Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.2.1 Abbott
- 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.1.2 Business Overview
- 1.2.1.3 Financials (Subject to data availability)
- 1.2.1.4 R&D Investment (Subject to data availability)
- 1.2.1.5 Product Types Specification
- 1.2.1.6 Business Strategy
- 1.2.1.7 Recent Developments
- 1.2.1.8 Management Change
- 1.2.1.9 S.W.O.T Analysis
- 1.2.2 F. Hoffmann-LA Roche AG
- 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.2.2 Business Overview
- 1.2.2.3 Financials (Subject to data availability)
- 1.2.2.4 R&D Investment (Subject to data availability)
- 1.2.2.5 Product Types Specification
- 1.2.2.6 Business Strategy
- 1.2.2.7 Recent Developments
- 1.2.2.8 Management Change
- 1.2.2.9 S.W.O.T Analysis
- 1.2.3 Genomic Health
- 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.3.2 Business Overview
- 1.2.3.3 Financials (Subject to data availability)
- 1.2.3.4 R&D Investment (Subject to data availability)
- 1.2.3.5 Product Types Specification
- 1.2.3.6 Business Strategy
- 1.2.3.7 Recent Developments
- 1.2.3.8 Management Change
- 1.2.3.9 S.W.O.T Analysis
- 1.2.4 Inc.
- 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.4.2 Business Overview
- 1.2.4.3 Financials (Subject to data availability)
- 1.2.4.4 R&D Investment (Subject to data availability)
- 1.2.4.5 Product Types Specification
- 1.2.4.6 Business Strategy
- 1.2.4.7 Recent Developments
- 1.2.4.8 Management Change
- 1.2.4.9 S.W.O.T Analysis
- 1.2.5 QIAGEN
- 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.5.2 Business Overview
- 1.2.5.3 Financials (Subject to data availability)
- 1.2.5.4 R&D Investment (Subject to data availability)
- 1.2.5.5 Product Types Specification
- 1.2.5.6 Business Strategy
- 1.2.5.7 Recent Developments
- 1.2.5.8 Management Change
- 1.2.5.9 S.W.O.T Analysis
- 1.2.6 Agilent Technologies
- 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.6.2 Business Overview
- 1.2.6.3 Financials (Subject to data availability)
- 1.2.6.4 R&D Investment (Subject to data availability)
- 1.2.6.5 Product Types Specification
- 1.2.6.6 Business Strategy
- 1.2.6.7 Recent Developments
- 1.2.6.8 Management Change
- 1.2.6.9 S.W.O.T Analysis
- 1.2.7 Inc.
- 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.7.2 Business Overview
- 1.2.7.3 Financials (Subject to data availability)
- 1.2.7.4 R&D Investment (Subject to data availability)
- 1.2.7.5 Product Types Specification
- 1.2.7.6 Business Strategy
- 1.2.7.7 Recent Developments
- 1.2.7.8 Management Change
- 1.2.7.9 S.W.O.T Analysis
- 1.2.8 AGENDIA N.V.
- 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.8.2 Business Overview
- 1.2.8.3 Financials (Subject to data availability)
- 1.2.8.4 R&D Investment (Subject to data availability)
- 1.2.8.5 Product Types Specification
- 1.2.8.6 Business Strategy
- 1.2.8.7 Recent Developments
- 1.2.8.8 Management Change
- 1.2.8.9 S.W.O.T Analysis
- 1.2.9 bioMérieux SA
- 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.9.2 Business Overview
- 1.2.9.3 Financials (Subject to data availability)
- 1.2.9.4 R&D Investment (Subject to data availability)
- 1.2.9.5 Product Types Specification
- 1.2.9.6 Business Strategy
- 1.2.9.7 Recent Developments
- 1.2.9.8 Management Change
- 1.2.9.9 S.W.O.T Analysis
- 1.2.10 Illumina
- 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.10.2 Business Overview
- 1.2.10.3 Financials (Subject to data availability)
- 1.2.10.4 R&D Investment (Subject to data availability)
- 1.2.10.5 Product Types Specification
- 1.2.10.6 Business Strategy
- 1.2.10.7 Recent Developments
- 1.2.10.8 Management Change
- 1.2.10.9 S.W.O.T Analysis
- 1.2.11 Inc.
- 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.11.2 Business Overview
- 1.2.11.3 Financials (Subject to data availability)
- 1.2.11.4 R&D Investment (Subject to data availability)
- 1.2.11.5 Product Types Specification
- 1.2.11.6 Business Strategy
- 1.2.11.7 Recent Developments
- 1.2.11.8 Management Change
- 1.2.11.9 S.W.O.T Analysis
- 1.2.12 Siemens Healthineers
- 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.12.2 Business Overview
- 1.2.12.3 Financials (Subject to data availability)
- 1.2.12.4 R&D Investment (Subject to data availability)
- 1.2.12.5 Product Types Specification
- 1.2.12.6 Business Strategy
- 1.2.12.7 Recent Developments
- 1.2.12.8 Management Change
- 1.2.12.9 S.W.O.T Analysis
- 1.2.13 Thermo Fisher Scientific Inc.
- 1.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.13.2 Business Overview
- 1.2.13.3 Financials (Subject to data availability)
- 1.2.13.4 R&D Investment (Subject to data availability)
- 1.2.13.5 Product Types Specification
- 1.2.13.6 Business Strategy
- 1.2.13.7 Recent Developments
- 1.2.13.8 Management Change
- 1.2.13.9 S.W.O.T Analysis
- 1.2.14 BioGenex
- 1.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.14.2 Business Overview
- 1.2.14.3 Financials (Subject to data availability)
- 1.2.14.4 R&D Investment (Subject to data availability)
- 1.2.14.5 Product Types Specification
- 1.2.14.6 Business Strategy
- 1.2.14.7 Recent Developments
- 1.2.14.8 Management Change
- 1.2.14.9 S.W.O.T Analysis
- 1.2.1 Abbott
- 1.1 Top Competitors Analysis
Chapter 2. Global Companion Diagnostic Tests Market Analysis
- 2.1 Global Companion Diagnostic Tests Market Analysis
- 2.2 Global Companion Diagnostic Tests Market Analysis by Region
- 2.3 Global Companion Diagnostic Tests Market Analysis by By Product Type Outlook:
- 2.4 Global Companion Diagnostic Tests Market Analysis by By Cancer Type Outlook:
- 2.5 Global Companion Diagnostic Tests Market Analysis by By End-User Outlook:
- 2.6 Global Companion Diagnostic Tests Market Analysis by Key Players
Chapter 3. North America Companion Diagnostic Tests Market Analysis
- 3.1 North America Companion Diagnostic Tests Market Analysis
- 3.2 North America Companion Diagnostic Tests Market Analysis by Country
- 3.3 North America Companion Diagnostic Tests Market Analysis by By Product Type Outlook:
- 3.4 North America Companion Diagnostic Tests Market Analysis by By Cancer Type Outlook:
- 3.5 North America Companion Diagnostic Tests Market Analysis by By End-User Outlook:
- 3.6 North America Companion Diagnostic Tests Market Analysis by Key Players
Chapter 4. Europe Companion Diagnostic Tests Market Analysis
- 4.1 Europe Companion Diagnostic Tests Market Analysis
- 4.2 Europe Companion Diagnostic Tests Market Analysis by Country
- 4.3 Europe Companion Diagnostic Tests Market Analysis by By Product Type Outlook:
- 4.4 Europe Companion Diagnostic Tests Market Analysis by By Cancer Type Outlook:
- 4.5 Europe Companion Diagnostic Tests Market Analysis by By End-User Outlook:
- 4.6 Europe Companion Diagnostic Tests Market Analysis by Key Players
Chapter 5. Asia Pacific Companion Diagnostic Tests Market Analysis
- 5.1 Asia Pacific Companion Diagnostic Tests Market Analysis
- 5.2 Asia Pacific Companion Diagnostic Tests Market Analysis by Country
- 5.3 Asia Pacific Companion Diagnostic Tests Market Analysis by By Product Type Outlook:
- 5.4 Asia Pacific Companion Diagnostic Tests Market Analysis by By Cancer Type Outlook:
- 5.5 Asia Pacific Companion Diagnostic Tests Market Analysis by By End-User Outlook:
- 5.6 Asia Pacific Companion Diagnostic Tests Market Analysis by Key Players
Chapter 6. South America Companion Diagnostic Tests Market Analysis
- 6.1 South America Companion Diagnostic Tests Market Analysis
- 6.2 South America Companion Diagnostic Tests Market Analysis by Country
- 6.3 South America Companion Diagnostic Tests Market Analysis by By Product Type Outlook:
- 6.4 South America Companion Diagnostic Tests Market Analysis by By Cancer Type Outlook:
- 6.5 South America Companion Diagnostic Tests Market Analysis by By End-User Outlook:
- 6.6 South America Companion Diagnostic Tests Market Analysis by Key Players
Chapter 7. Middle East Companion Diagnostic Tests Market Analysis
- 7.1 Middle East Companion Diagnostic Tests Market Analysis
- 7.2 Middle East Companion Diagnostic Tests Market Analysis by Country
- 7.3 Middle East Companion Diagnostic Tests Market Analysis by By Product Type Outlook:
- 7.4 Middle East Companion Diagnostic Tests Market Analysis by By Cancer Type Outlook:
- 7.5 Middle East Companion Diagnostic Tests Market Analysis by By End-User Outlook:
- 7.6 Middle East Companion Diagnostic Tests Market Analysis by Key Players
Chapter 8. Africa Companion Diagnostic Tests Market Analysis
- 8.1 Africa Companion Diagnostic Tests Market Analysis
- 8.2 Africa Companion Diagnostic Tests Market Analysis by Country
- 8.3 Africa Companion Diagnostic Tests Market Analysis by By Product Type Outlook:
- 8.4 Africa Companion Diagnostic Tests Market Analysis by By Cancer Type Outlook:
- 8.5 Africa Companion Diagnostic Tests Market Analysis by By End-User Outlook:
- 8.6 Africa Companion Diagnostic Tests Market Analysis by Key Players
Chapter 9. By Product Type Outlook: Analysis
- 9.1 Detection Technique
- 9.1.1 Global Detection Technique Market
- 9.1.2 Global Detection Technique Market by Region
- 9.2 Protein Detection
- 9.2.1 Global Protein Detection Market
- 9.2.2 Global Protein Detection Market by Region
- 9.3 Immunohistochemistry
- 9.3.1 Global Immunohistochemistry Market
- 9.3.2 Global Immunohistochemistry Market by Region
- 9.4 DNA Detection
- 9.4.1 Global DNA Detection Market
- 9.4.2 Global DNA Detection Market by Region
- 9.5 Polymerase Chain Reaction (PCR)
- 9.5.1 Global Polymerase Chain Reaction (PCR) Market
- 9.5.2 Global Polymerase Chain Reaction (PCR) Market by Region
- 9.6 Next-generation Sequencing (NGS)
- 9.6.1 Global Next-generation Sequencing (NGS) Market
- 9.6.2 Global Next-generation Sequencing (NGS) Market by Region
- 9.7 In Situ Hybridization
- 9.7.1 Global In Situ Hybridization Market
- 9.7.2 Global In Situ Hybridization Market by Region
- 9.8 Others
- 9.8.1 Global Others Market
- 9.8.2 Global Others Market by Region
- 9.9 Biomarker
- 9.9.1 Global Biomarker Market
- 9.9.2 Global Biomarker Market by Region
- 9.10 EGFR
- 9.10.1 Global EGFR Market
- 9.10.2 Global EGFR Market by Region
- 9.11 KRAS
- 9.11.1 Global KRAS Market
- 9.11.2 Global KRAS Market by Region
- 9.12 HER2
- 9.12.1 Global HER2 Market
- 9.12.2 Global HER2 Market by Region
- 9.13 BRAF V600E
- 9.13.1 Global BRAF V600E Market
- 9.13.2 Global BRAF V600E Market by Region
- 9.14 Others
- 9.14.1 Global Others Market
- 9.14.2 Global Others Market by Region
- 9.1 Detection Technique
Chapter 10. By Cancer Type Outlook: Analysis
- 10.1 Breast Cancer
- 10.1.1 Global Breast Cancer Market
- 10.1.2 Global Breast Cancer Market by Region
- 10.2 Lung Cancer
- 10.2.1 Global Lung Cancer Market
- 10.2.2 Global Lung Cancer Market by Region
- 10.3 Colorectal Cancer
- 10.3.1 Global Colorectal Cancer Market
- 10.3.2 Global Colorectal Cancer Market by Region
- 10.4 Liver Cancer
- 10.4.1 Global Liver Cancer Market
- 10.4.2 Global Liver Cancer Market by Region
- 10.5 Melanoma
- 10.5.1 Global Melanoma Market
- 10.5.2 Global Melanoma Market by Region
- 10.6 Others
- 10.6.1 Global Others Market
- 10.6.2 Global Others Market by Region
- 10.1 Breast Cancer
Chapter 11. By End-User Outlook: Analysis
- 11.1 Hospitals
- 11.1.1 Global Hospitals Market
- 11.1.2 Global Hospitals Market by Region
- 11.2 Specialty Clinics
- 11.2.1 Global Specialty Clinics Market
- 11.2.2 Global Specialty Clinics Market by Region
- 11.3 Diagnostic Labs
- 11.3.1 Global Diagnostic Labs Market
- 11.3.2 Global Diagnostic Labs Market by Region
- 11.4 Others
- 11.4.1 Global Others Market
- 11.4.2 Global Others Market by Region
- 11.1 Hospitals
Chapter 12. Qualitative Analysis (Subject to Data Availability)
- 12.1 Market Drivers
- 12.2 Market Restraints
- 12.3 Market Trends
- 12.4 Market Opportunity
- 12.5 Technological Road Map (Subject to Data Availability)
- 12.6 Product Life Cycle (Subject to Data Availability)
- 12.7 Customer and Buyer Behavior Analysis
- 12.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 12.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 12.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 12.7.4 Pricing, Affordability & Value Perception Analysis
- 12.7.5 Customer Segmentation & Demand Pattern Analysis
- 12.8 PESTEL Analysis
- 12.8.1 Political Factors
- 12.8.2 Economic Factors
- 12.8.3 Social Factors
- 12.8.4 Technological Factors
- 12.8.5 Legal Factors
- 12.8.6 Environmental Factors
- 12.9 Industrial Chain Analysis (Subject to Data Availability)
- 12.9.1 Industry Chain Analysis
- 12.9.2 Manufacturing Cost Analysis
- 12.9.3 Supply Side Analysis
- 12.9.3.1 Raw Material Analysis
- 12.9.3.2 Raw Material Procurement Analysis
- 12.9.3.3 Raw Material Price Trend Analysis
- 12.10 Porter’s Five Forces Analysis
- 12.10.1 Bargaining Power of Suppliers
- 12.10.2 Bargaining Power of Buyers
- 12.10.3 Threat of New Entrants
- 12.10.4 Threat of Substitutes
- 12.10.5 Degree of Competition
- 12.11 Patent Analysis (Subject to Data Availability)
- 12.12 ESG Analysis
- 12.13 Geopolitical Outlook
- 12.13.1 Global Power Realignment & Strategic Alliances
- 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 12.13.3 International Trade Relations & Market Access Environment
- 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 12.13.6 Technology Sovereignty & Digital Geopolitics
- 12.13.7 Strategic Implications for Investment, Growth & Market Entry
- 12.14 AI & Market Transformation
- 12.14.1 Competitive Landscape Disruption & Strategic Shifts
- 12.14.2 AI-Driven Transformation of Industry Value Chain
- 12.14.3 Evolution of Business Models & Revenue Streams
- 12.14.4 AI-Driven Product, Service & Innovation Transformation
- 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 13. TOP 10 Country Analysis
- 13.1 Country 1
- 13.2 Country 2
- 13.3 Country 3
- 13.4 Country 4
- 13.5 Country 5
- 13.6 Country 6
- 13.7 Country 7
- 13.8 Country 8
- 13.9 Country 9
- 13.10 Country 10
Chapter 14. Research Findings
- 14.1 Key Takeaways
- 14.2 Analyst Point of View
- 14.3 Assumptions and Acronyms
Chapter 15. Research Methodology and Sources
- 15.1 Primary Data Collection
- 15.1.1 Steps for Primary Data Collection
- 15.1.1.1 Identification of KOL
- 15.1.2 Backward Integration
- 15.1.3 Forward Integration
- 15.1.4 How Primary Research Help Us
- 15.1.5 Modes of Primary Research
- 15.1.1 Steps for Primary Data Collection
- 15.2 Secondary Research
- 15.2.1 How Secondary Research Help Us
- 15.2.2 Sources of Secondary Research
- 15.3 Data Validation
- 15.3.1 Data Triangulation
- 15.4 Data Representation
- 15.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Companion Diagnostic Tests Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Medical Devices & Consumables Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Companion Diagnostic Tests Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the companion diagnostic tests market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
